Welcome to the CRASH 2015 Trauma Panel

• 2nd annual CRASH Trauma Panel
• Nontraditional (and informal) format: four 20-25 minute “discussion-stimulating presentations” followed by Q&A.
• All presentations are available on the CRASH website
• Panelists have no conflicts of interest.
• Trauma Panelists:
  – Dr. Matthew Roberts
  – Dr. Beth Benish
  – Dr. Ami Riggert
  – Dr. Mark Chandler-Facilitator

Trauma Update 2015: Part 1

• Ratio Wars
  – PROMMTT
  – PROPRR
  – Crystalloid to RBCs
• Whole Blood
• Ketamine
• TEG in Trauma Resuscitation
• Trauma Anesthesiology Society

Trauma Update 2015: Part 2 (Beth Benish, MD)

• PCC4 Prothrombin Complex Concentrate in Trauma
• Fibrinogen concentrate
• TXA and Factor 7
• Trauma checklist
• Hypotensive resuscitation

Trauma...

...is the second leading cause of death worldwide.
...is the third leading cause of death in the US.
...is the leading cause of death among people ages 1 and 44 years in the US.
...is the leading cause of years of life lost for people <75 years old in the US.
...has increased as a cause of deaths 23% during the last decade in the US.
...is the leading cause for anesthesia providers to unexpectedly and suddenly wish, at some complacent point after training, “that I had paid attention to how to do this while I was still training…”

Approximately 20% to 40% of trauma deaths after hospital admission involve massive hemorrhage from truncal injury and are potentially preventable with rapid hemorrhage control/improved resuscitation.
Ratio Wars

Ratio Wars: background
• Traditional trauma ratio: crystalloid → pRBCs → other blood products.
• Iraq/Afghanistan experiences: Damage Control Resuscitation (DCR), higher ratios of FFP, PLTs, cryo to RBCs more effective
• The debate begins:
  — Borgman MA. et. al. The Ratio of Blood Products Affects Mortality in Patients Receiving Massive Transfusions at a Combat Support Hospital, J Trauma 2007;63: 805-813

PROMMTT Study 2013: Background
• Goal: “To relate in-hospital mortality to early transfusion of FFP and/or PLTs and to time-varying FFP:RBC and PLT:RBC ratios
• Prospective, observational cohort study at 10 level I TCs.
• Adult trauma patients, highest level of trauma activation, surviving 30 min. after admission:
  • Received at least 1 unit RBCs within 6 hrs. of admission (n=1245, original study group),
  • Received 3 total units (RBCs, plasma, or platelets) within 24 hours (n=905, the analysis group)
• Main outcome: In-hospital mortality
• “We hypothesized that early transfusion of plasma and platelets in higher ratios would be associated with decreased in-hospital mortality in bleeding patients.”

PROMMTT Study 2013: Results
• FFP:RBC and PLT:RBC ratios were inconsistent for first 24 hrs (both P<.001) across trauma centers, within trauma centers, and within a single patient’s course of care.
• In the first 6 hours, patients with ratios (FFP: RBC and PLT:RBC) less than 1:2 were 3 to 4 times more likely to die than patients with ratios of 1:1 or higher.
• After 24 hours, plasma and platelet ratios were unassociated with mortality, when competing risks from nonhemorrhagic causes prevailed.

PROPPR RCT 2015: Background

- **Goal:** “Compare the effectiveness and safety of a 1:1:1 transfusion ratio of plasma, platelets, and RBCs to a 1:1:2 ratio.”
- **Phase III trial at 12 Level I trauma Centers.**
- **August 2012-December 2013.**
- **Primary Outcome:** 24-hour and 30-day all-cause mortality.
- **Prespecified Ancillary Outcomes:**
  - Time to hemostasis
  - Blood product volumes transfused
  - Complications
  - Incidence of surgical procedures
  - Functional status.

PROPPR RCT 2015: Methods-products

- Randomized pre-packed sealed containers to bedside in 10 minutes.
- Rigidly controlled until hemostasis, death, declaration of futility; thereafter no control of resuscitation.

**Table 1:**

<table>
<thead>
<tr>
<th>Container</th>
<th>Group 1</th>
<th>Group 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelets</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Plasma</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>RBCs</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Plasma</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>RBCs</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

* Group 1: Platelets first, then alternate RBCs and Plasma, as clinically required. * Group 2: Platelets first (if available), then alternate 2 RBCs and 1 Plasma, as clinically required. The container cycles were repeated until hemostasis was achieved and resuscitation completed.

PROPPR RCT 2015: Results

- **Mortality at 24 hours:** 12.7% (1:1:1) vs 17.0% (1:1:2) group (difference, −4.2% [95% CI, −9.6% to 1.1%]; P = .12).
- **Mortality at 30 days:** 22.4% vs 26.1%, respectively (difference, −3.7% [95% CI, −10.2% to 2.7%]; P = .26).
PROPPR RCT 2015: Results

- Exsanguination ↓ in 1:1:1 group (9.2% vs 14.6%; P = .03).
- Hemostasis ↑ in 1:1:1 group (86% vs 78%; P = .006).
- Despite more FFP (median of 7U vs 5U, P < .001), PLTs (12 U vs 6 U, P < .001) and similar amounts of red blood cells (9 U) in 1:1:1 over the first 24 hrs., no differences in 23 prespecified complications (including ARDS, MOF, VTE, sepsis, transfusion related comps).
- Laboratory-guided “catching up” after controlled, ratio driven products occurred in 1:1:2, such that cumulative ratios approached 1:1:1.

Neal MD, et. al. When a little goes a long way: Background

- Despite multiple studies FFP/PLTS/CRYO:PRBCs ratios, little research on crystalloid:pRBC ratio appropriate in Massive Transfusion.
- Hypothesis: An increased crystalloid PRBC (C:PRBC) ratio would be associated with increased morbidity and poor outcome after MT.
- Primary outcomes interest: in-house mortality, Nosocomial infection (NI), Multi-organ failure (MOF), Acute Respiratory Distress Syndrome (ARDS), Abdominal Compartment Syndrome (ACS)
- 7 institutions, Nov 2003-October 2008

PROPPR RCT 2015: Conclusion

“Given the lower percentage of deaths from exsanguination and our failure to find differences in safety, clinicians should consider using a 1:1:1 transfusion protocol, starting with the initial units transfused while patients are actively bleeding, and then transitioning to laboratory-guided treatment once hemorrhage control is achieved.”

Neal MD, et. al. When a little goes a long way: Results

- 1710 blunt injured patients, 452 enrolled (required MT and survived beyond 24 hrs); mean ISS=34.
- Cohort’s median transfusion/1st 24 hrs.: 17 L crystalloid; 16u pRBCs; 8.4u FFP; 1.6u PLTs .
- Overall in-hospital mortality : 22.6%; MOF: 63.5%; NI: 56.2%; ARDS: 36.3%; ACS: 15.1%.
- Importantly, as C:PRBC ratio increased, volume of blood component transfusion significantly decreased.


Neal MD, et. al. When a little goes a long way: Results

- Regression analysis revealed that a C:RBC ratio of >1.5:1 increased the following Odds Ratios:
  - MOF: OR, 2.6; 95% CI, 1.2-5.4; p =0.011
  - ARDS: OR, 2.5; 95% CI, 1.2-4.9; p =0.010
  - ACS: OR, 3.6; 95% CI, 1.3-9.7; p =0.009
Neal MD, et. al. When a little goes a long way: Results

- The independent risk of MOF associated with a C:PRBC ratio 1.5:1 was strongest, significant, and most pertinent to patients who received a low FFP:PRBC ratio (OR=5.9; 95% CI, 1.8–19; p =0.003).

Neal MD, et. al. When a little goes a long way: Conclusion

- "These results suggest that high-volume crystalloid and low-volume FFP resuscitation may create a worst case scenario and identify a patient cohort and resuscitation strategy at particularly elevated risk for MOF."
- "It may be that in the absence of aggressive treatment of the early coagulopathy postinjury, the risk of crystalloids promoting an excessive inflammatory response is accentuated."
- "Similarly, obviating FFP resuscitation with crystalloid resuscitation may overwhelm the already primed innate immune response and results in higher organ failure and poor outcome." inflammatory system is tipped over the edge.

WHOLE BLOOD BACKGROUND

- Whole Blood (WB) has been the traditional transfusion product in trauma since WWII.
- Component therapy introduced in 1960s-70s.
- WB resurfaces as “ideal” resuscitation product during subsequent military conflicts.
- OIF/OEF:
  - >10,000 U WB transfused to US Personnel to date.
  - Series of articles emerge heralding WB use in trauma.

Cotton BA, et. al. RCT trial mWB vs. CT: Background

- Single-center, randomized pilot trial, primary outcome: 24-hour transfusion volume.
- Primary Outcome: 24-hr. transfusion volumes.
- Sponsored by the Department of Defense.
- Hypothesis: “...resuscitation of severely injured patients with modified whole blood (mWB) would result in fewer overall transfusions compared with component (COMP) therapy.”

Cotton BA, et al. RCT: mWB vs. CT:

**Methods**

- **mWB Cohort:** 1 U mWB on arrival. Then 6 U mWB + 1 U PLTs
- **COMP Cohort:** 1 U RBC + 1 U plasma on arrival. Then 6 U RBC + 6 U plasma + 1 U PLTs

**Cotton BA, et al., RCT: mWB vs. CT**

- **1st outcome:** WB not superior to CT in blood product utilization.

<table>
<thead>
<tr>
<th>WB Group (n = 33)</th>
<th>COMP Group (n = 34)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median 24-hr RBC transfusions, U</td>
<td>4 (2, 6)</td>
<td>6 (2, 13)</td>
</tr>
<tr>
<td>Median 24-hr plasma transfusions, U</td>
<td>4 (2, 7)</td>
<td>6 (2, 14)</td>
</tr>
<tr>
<td>Median 24-hr platelet transfusions, U</td>
<td>0 (0, 1)</td>
<td>1 (0, 2)</td>
</tr>
<tr>
<td>Median 24-hr total transfusions, U</td>
<td>11 (5, 17)</td>
<td>16 (4, 41)</td>
</tr>
<tr>
<td>24-hr mortality, %</td>
<td>6%</td>
<td>9%</td>
</tr>
<tr>
<td>30-d mortality, %</td>
<td>6%</td>
<td>9%</td>
</tr>
</tbody>
</table>

- Sensitivity analysis (patients without severe TBI) use of mWB significantly reduced transfusion volumes.

---

Ketamine

- Phencyclidine derivative: NMDA receptor antagonist, also binds opioid mu & sigma receptors (analgesic & anesthetic)

- **pKa of 7.5,** ~50% dissociated @ pH 7.45; 12% bound to plasma proteins (rapid blood-brain equilibration & clinical onset)
- Developed by Parke-Davis in 1962; safer anesthetic than phencyclidine
- Recreational street drug: “K,” “Special K” and “Vitamin K” (made Schedule III drug in 1999)
- Raises ICP? Strictly an OR drug?

Zeiler, et. Al. Ketamine on ICP in TBI: results

- In some neurosurgical/neuroanesthesia literature, same four studies are cited as evidence for urge caution using ketamine in neurologically ill:
- All four studies focus on ketamine as a dissociative anesthetic for elective neurosurgical procedures (mainly shunt revisions).
- Few actual patient cases described; those described showed post-ketamine ICP elevation measured via ventricular or lumbar catheter.
- Proposed mechanism: large vessel vasodilation vs. small vessel vasoconstriction related to NO synthase inhibition.

Zeiler, et. Al. Ketamine on ICP in TBI: results and conclusion

- 7 articles: 156 patients (101 adults 55 pediatric), varying doses of ketamine
  - 4 articles compare ketamine vs. opiate infusions: all 4 found no difference in ICP/fluctuations, equal sedative properties
  - 3 articles focus on bolus ketamine to prevent ↑ICP during stimulus or to ↓ICP during acute elevation: all 3 studies cited trend toward ↓ICP with ketamine bolus, and sustained effect when used pre-emptively for stimulating procedures.
- Authors make an “Oxford 2b,” and “GRADE C” that ketamine does not lead to a elevation in ICP in severe TBI, in the setting of an intubated and sedated patient.

Ketamine in the Prehospital Setting

Fisher AD, et. al. Prehospital Ketamine for Combat Wounds: Background

- TCCC (10/2013) ketamine: for “casualty unable to remain in the fight:”
  - 50-100 mg IM /50 mg IN; Q 30-60 min (until pain controlled or nystagmus)
  - If IV/IO access, 20 mg slow push, repeat Q 5-10 min
- 2009: 75th Ranger Regiment (75RR) implements ketamine protocol that exceeds TCCC recommendations (RMHB 4th edition):
  - Basic Pain Management Protocol:
    - 1st line: Oral Transmucosal Fentanyl Citrate (OTFC)
    - 2nd line: ketamine 250 mg IM vs. morphine 10 mg IV vs. hydromorph 2 mg IV.
  - Advanced Pain Management Protocol
    - 1st Line: OTFC
    - 2nd line: midazolam 2mg w/ketamine 75 mg IV/IO followed by 20-25 mg increments OR Ketamine 250 mg IM
- Retrospective analysis of 75RR’s PHTR 1/09-10/14 for ketamine use at the POI

Fisher AD, et. al. Prehospital Ketamine for Combat Wounds: Results

- “The extremity movement made it difficult to move a patient through heavy brush and the incoherent speech was above the normal volume of speech, however, it is not known if it caused unnecessary attention from the enemy…”
- “One patient developed a period of apnea after receiving ketamine and midazolam…the move was made more difficult by the sporadic gunfire from the enemy and suppressive fire from attack helicopter; the patient was moving his extremities throughout this time…”

Fisher AD, et. al. Prehospital Ketamine for Combat Wounds: Conclusion

- “Ketamine appears to be a safe and effective as a dissociative agent and an analgesic in the prehospital setting.”
- “It has a superior safety profile when used in a combat trauma setting, with none of the undesirable side effects of opioids.”
- “It is recommended that the US FDA authorize the use of ketamine for analgesia.”
Thromboelastography (TEG)


Thromboelastography: background

- TEG first described in 1948 by Dr. Hellmut Hartert of Heidelberg, has been used to evaluate coagulation profiles for >60 years
- 1967, Hardway, et. al. uses TEG to describe coagulation changes seen in combat casualties in Vietnam.
- Rapid TEG (rTEG) uses tissue factor instead of kaolin, further speeding reaction and clot formation

Holcomb JB, et. al. Admission rTEG vs. CCT, 2012: background

- Single Center, retrospective cohort study
- September 2009-February 2011
- Both CCTs (PT, PTT, INR, PLT, fibrinogen) and rTEG obtained on all trauma patients upon arrival
- 1974 patients enrolled
- Hypothesis: “rTEG would provide more useful and cost-effective evaluation of the coagulation system than multiple CCTs”

Holcomb JB, et. al. Admission rTEG vs. CCT, 2012: results

- When controlling for age, injury mechanism, weighted-revised Trauma Score, base excess and hemoglobin:
  - ACT predicted RBC transfusion.
  - α-angle predicted massive RBC transfusion better than PT/aPTT or INR (P < 0.001).
  - α-angle was superior to fibrinogen for predicting plasma transfusion (P < 0.001).
  - MA was superior to PLT for predicting platelet transfusion (P < 0.001).
  - LY-30 documented fibrinolysis.
- These correlations improved for transfused, shocked or head injured patients.
- The charge for r-TEG ($317) was similar to the 5 CCTs ($286).
<table>
<thead>
<tr>
<th>Laboratory Values</th>
<th>Blood Product Transfusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACT &gt; 128</td>
<td>Plasma and RBCs</td>
</tr>
<tr>
<td>r-value &gt; 1.1</td>
<td>Plasma and RBCs</td>
</tr>
<tr>
<td>K-time &gt; 2.5</td>
<td>Cryoprecipitate / fibrinogen / plasma</td>
</tr>
<tr>
<td>a-angle &lt; 56</td>
<td>Cryoprecipitate / fibrinogen / platelets</td>
</tr>
<tr>
<td>MA &lt; 55</td>
<td>Platelets / cryoprecipitate / fibrinogen</td>
</tr>
<tr>
<td>LY30 &gt; 3%</td>
<td>Tranexamic acid</td>
</tr>
<tr>
<td>PT &gt; 18.0</td>
<td>Plasma</td>
</tr>
<tr>
<td>aPTT &gt; 35</td>
<td>Plasma</td>
</tr>
<tr>
<td>INR &gt; 1.5</td>
<td>Plasma</td>
</tr>
<tr>
<td>Platelet count &lt; 150 x 10^11/L</td>
<td>Platelets</td>
</tr>
<tr>
<td>Fibrinogen &lt; 180 g/L</td>
<td>Cryoprecipitate / fibrinogen</td>
</tr>
</tbody>
</table>

Questions?

Trauma Anesthesia Society

- Founded in 2011
- Over 200 members
- Access to monthly Newsletter containing updates in research, literature reviews, and society news
- Access to Trauma Anesthesia Digest
- Active membership: $100, associate membership is $75, residents are $25.